Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. - Wikidata - awgldk - TriplyDB

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

http://www.wikidata.org/entity/Q37238720

about

The role of adaptive trial designs in drug development.The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

P2860

Q38691922-5F5D5345-E444-4004-BBA4-38E014B34A4A Q42382909-C0EA4866-D490-4690-BF1F-8E37C8C53727

P2860

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

http://www.wikidata.org/entity/Q37238720

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 December 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

@en

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

@nl

type

label

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

@en

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

@nl

prefLabel

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

@en

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

@nl

P1433

Q37238720-C64E274F-107D-4E00-B48E-107FDECAE73B

P1476

Q37238720-3A7F0F78-1C39-4220-BC10-28E446F8F1C7

P2093

Q37238720-6FD4D568-AD00-44B8-8E17-58FCD4D53D65

Q37238720-D738EB93-CDCE-41B9-9091-14DC0170A76A

Q37238720-DD248BCC-FC8D-4CCB-ACC7-1E09B2357D79

Q37238720-F52F3A40-A179-4A17-916B-35E761E933CE

Q37238720-F5F1D9E6-DFC4-41CF-B091-2630AE7C2B02

P2860

Q37238720-06B73D03-CB9E-4606-8C42-13339154F735

Q37238720-12105E6B-E318-45EF-AA22-EE9BF2DCD8F6

Q37238720-215FC85D-CBCD-4F7D-A077-097B590A7CD3

Q37238720-2E1E625C-6573-4A5A-80F0-2781151AE6DA

Q37238720-2EF69984-F8FD-4263-9AAC-2A1E563B41E0

Q37238720-3CFD5542-20B3-49EB-A15E-E84DB251DF75

Q37238720-3D3CB289-371D-414B-AA28-C4FD82B25701

Q37238720-4B7B8725-4C22-489A-8BF4-AC9A288FA42A

Q37238720-4D6F36A8-C244-401F-B49B-A633B26B53AC

Q37238720-5119F07C-B6AF-41F7-B0B4-980D7C1762AE

P2888

Q37238720-377DFD8C-F485-416B-9010-40A7B3549FFC

P304

Q37238720-0C7AC09A-C87D-491A-BC22-772CC39CF950

P31

Q37238720-9B1A023F-4E19-441C-9638-F29CFA5FEEC9

P356

Q37238720-19D161DF-A5E5-49A7-92AD-15E57598F5F3

P433

Q37238720-D7BC4D91-9E15-4274-9830-504889FCA3E5

P478

Q37238720-40AD76E9-56CA-4852-9397-0F651D071752

P50

Q37238720-228124FE-188D-4F77-B657-7C500D83729E

Q37238720-2D6EE97C-0D8F-4732-8C7F-B4420043E5AC

P577

Q37238720-87569E96-E844-4EF9-9945-0479AF5A1F20

P698

Q37238720-9E65B977-4B20-456D-BB04-B5C1EA781D6D

P921

Q37238720-2B0EBEF4-2755-4955-B764-022796D362D9

P932

Q37238720-21C0AA59-1DC9-45D8-A1FF-CDB4C9126AC4

P356

S12561-014-9124-2

P1433

Statistics in biosciences

P1476

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

@en

P2093

Caimiao Wei

http://www.w3.org/2001/XMLSchema#string

J Jack Lee

http://www.w3.org/2001/XMLSchema#string

Nan Chen

http://www.w3.org/2001/XMLSchema#string

Suyu Liu

http://www.w3.org/2001/XMLSchema#string

Xuemin Gu

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

The price of innovation: new estimates of drug development costs

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Can the pharmaceutical industry reduce attrition rates?

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.

An accelerated pathway for targeted cancer therapies.

P2888

s12561-014-9124-2

P304

99-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12561-014-9124-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Vassiliki Papadimitrakopoulou

P577

2014-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27617040

http://www.w3.org/2001/XMLSchema#string

P921

P932

5014437

http://www.w3.org/2001/XMLSchema#string